Our Research

BUILDING A COMMUNITY FOR CHANGE

The patient advocacy community seeks support from the biopharmaceutical industry to enhance its capacity. Similarly, Archo aims to establish strategic partnerships with the top experts & organizations in patient education, community outreach, innovative solutions development, & unconventional thinking to facilitate smooth, plug-and-play integrations. This approach promotes the creation of novel, outside-the-box solutions to meet the diverse needs of patients everywhere.

ELAVAY: PATIENT INSIGHTS. ELEVATED HEALTHCARE

Building the Bridge between patients, advocates & the for-profit healthcare industry

  • Pharmaceutical & Biotech
  • male and female
  • Medical Device
  • Genomics Laboratories
  • Payers, PBMs & Specialty Pharmacy
Our research guides these organizations to respond by ensuring the patient remains at the center of all decision-making & allowing for course correction.
ELAVAY is a group of syndicated market research reports that are run annually to gain a deeper understanding of patient advocacy, professional society, and community-based organization experience in engaging with pharmaceutical, biotech, medical device, payer and PBM patient advocacy/engagement teams. Each year, these teams struggle to educate their senior leadership and c-suite executives on the impact they have had in a quantifiable way. Elavay fills the void with annual feedback from the voice of their customers. This feedback, both quantitative and qualitative, can then be utilized to drive deeper strategic planning and execution to drive patient engagement & maximize patient outcomes.

Cutting-edge data collection & focus areas to maximize the impact of healthcare companies.

Insights collected include:

Stack Ranking Healthcare Organizations by PAOs/PSs:
    • Healthcare Companies Leading In Partnerships & Programs Support
    • Healthcare Companies Leading In Federal & State Government Policy-related Activities
    • Corporate Image & Reputation
    • Healthcare Companies Leading In Expanding Access & Education For Patient Treatment
    • Healthcare Companies Leading In Patient Advocacy & Community-based Organization Relationships

This year’s groundbreaking research introduces the first measures of their kind in healthcare, including:

Stack Ranking Healthcare Organizations by PAOs/PSs:

  • Healthcare Companies Leading In Diversity, Equity & Inclusion
  • Healthcare Companies Leading In Health Equity
  • Understanding the Activities of PAOs/PSs in
    • Health Disparities & Social Determinants Of Health: Activities In the Community
    • Patient-focused Medicine Development
    • Expanding Advocacy’s Focus & Community Engagement
    • Non-medical Switching & Its Impact On Today’s Patients
    • Healthcare Cost Offset Tactics & Their Impact On Patients: Copay Accumulators/Maximizers, & AFPs
    • Healthcare Policy & Patient Advocacy Understanding
    • Medicare Part D, IRA Drug Negotiations & Legislation
    • Telemedicine Utilization And Access/Use Issues
    • Employer Benefit Discussions

Customized Reporting Options. Scaled to meet customer needs & marketplace desires.

Elavay Sub-Reports

📊 ELAVAY: Patient Insights. Elevated Healthcare

Providing feedback to the for-profit industry to understand the expectations of customers and stakeholders they serve through an annual assessment to benchmark organizations across various industries.

📈 ELAVAY HEALTH EQUITY REPORT: The State of Health Equity & Social Determinants of Health

Uncovering the current landscape of market equity and consumer trends, driving actionable strategies to address disparities and promote inclusive access for all consumers.

🔬 ELAVAY ECHOS IN RESEARCH: Developing Medicines with a Focus on Patients

Exploring groundbreaking research methodologies centered on consumer needs, revolutionizing the product development process for enhanced efficacy and consumer-centric outcomes.

📚 ELAVAY POLICY PULSE: Healthcare Policy Education & Advocacy

Staying informed on the latest market research trends and advocacy efforts, empowering stakeholders with the knowledge to navigate complex market landscapes and drive positive change.

🤝 ELAVAY BIOADVOCATE BENCHMARK: Advocacy & Industry Dynamics

Aligning Strategically, Advocating Effectively, & Maximizing Impact. A streamlined toolkit to enhance advocacy impact and secure team support.

PARTNERSHIPS & PROGRAMS SUPPORT – INTEREST & SUPPORT

PARTNERSHIPS & PROGRAMS SUPPORT – INTEREST & SUPPORT

Bristol Myers Squibb and Janssen/Johnson & Johnson emerge as top performers, particularly excelling in Policy Discourse Opportunities and Payer Engagement Support. Merck also maintains a competitive position across various areas, showcasing strength in Federal Legislative Activity Events. However, relatively lower ratings for certain companies in segments like Government Outreach Guidance, State Legislative Activity Events and Federal Legislative Activity Events indicate potential areas for improvement in effectively navigating complex regulatory environments and fostering meaningful relationships with policymakers at different levels.

Areas Bristol Myers Squibb Janssen/Johnson & Johnson Merck Pfizer AstraZeneca Eli Lilly Takeda Takeda Amgen AbbVie
Policy Discourse Opportunities
5.71
5.23
5.21
4.44
4.70
4.72
4.74
5.04
4.65
4.42
Patient Care Comment Development
4.81
5.00
4.50
4.36
3.95
4.76
3.85
4.13
4.54
3.86
Payer Engagement Support
5.00
4.94
4.73
4.76
4.06
4.37
3.95
3.60
4.18
3.71
Policy Summaries & Briefings
4.70
4.88
4.60
4.48
4.45
3.86
4.36
4.27
3.70
3.36
Access Awareness & Education
4.95
4.97
4.38
4.45
4.05
4.05
4.20
3.65
3.60
3.00
Federal Legislative Activity Events
4.79
4.33
5.03
4.46
4.11
3.67
3.76
3.58
3.64
2.89
State Legislative Activity Events
4.43
4.38
4.06
4.28
4.05
3.78
4.06
4.00
3.44
3.25
Government Outreach Guidance
4.21
4.41
4.20
4.43
4.05
3.75
3.75
3.57
3.52
3.05
Average Ratings
4.82
4.77
4.59
4.46
4.18
4.12
4.08
3.98
3.91
3.44
Response Rate
26.32%
43.16%
28.42%
44.21%
26.32%
32.63%
26.32%
29.47%
30.53%
29.47%

PARTNERSHIPS & PROGRAMS SUPPORT – INTEREST & SUPPORT

Pfizer, Janssen/ Johnson & Johnson, Bristol-Myers Squibb, Eli-Lilly and Merck ranked highest in doing the most to advance Education & Change within Health Equity.

Pfizer
  • “Post-COVID initiatives, including sponsorship of health equity programs and fostering discussions.” Hematology, Patient Advocacy
  • “Pfizer’s proactive approach during COVID-19 and their focus on vaccine access” Non-Disease Specific, Patient Advocacy
  • “Pfizer has been traveling with a health equity billboard and station at various programs and events, in order to have these controversial discussions.“ Gastroenterology, Patient Advocacy
  • “Focused on looking at social determinants of health and how they can improve care for all patients”. Oncology: Breast, Patient Advocacy
  • “They provide funding and resources to address and improve health equity.” Director of Clinical Trials and Education, Patient Advocacy
  • “Pfizer has a health equity working group that has partnered with us to improve the awareness of health equity needs.” Senior Director, Justice, Equity, Diversity, Inclusion, Community Based Organization
  • “Pfizer also implements access programs to ensure that their medicines are available and affordable to patients in low-income or resource-limited settings and supports.” Oncology: Other, Patient Advocacy
Janssen/ Johnson & Johnson
  • “Recognized as a leader in health equity initiatives.” Cardiovascular, Patient Advocacy
  • “PAD mobile vans and education for underserved communities.“ .“ Cardiovascular, Professional Association
  • “Patient care tool kits can help patients mold their lifestyles“ Immunology: Rheumatology, Professional Association
  • “Janssen/J&J is a leader in this area with tremendous reach in the community oncology and academic medicine settings where every effort is being made to expand enrollment of diverse patient populations in clinical research and assure access to products in the pipeline.” Oncology: Pan-cancer, Patient Advocacy
  • “Consistently maintains open communication between itself and patients’ advocates regarding health and daily living issues.” Ophthalmology, Patient

ELAVAY BIOADVOCATE BENCHMARK: Advocacy & Industry Dynamics

Alternative Study Options

Providing industry insights on today’s trends and market realities of the pharmaceutical and biotech industry’s commitment to patient advocacy. The report includes insights such as:

  • Team size
  • Advocacy Team Alignment (Disease State / Region / US / Global)
  • Advocacy Budget
  • Where the budget is allocated from
  • Advocacy Budget vs Corporate Revenue
  • Corporate Alignment of Advocacy
  • IE: Part of Medical, Corporate Comms, Public Comms
  • Advocacy Team Identity

  • FEBRUARY

    Survey design, development, and programming. We will include the top 100 biopharmaceutical companies in the USA within the report respondent pool. We will work with our industry partners to identify which wholly-owned subsidiaries should remain as an independent measure vs. be part of the parent organization

  • MARCH

    Fielding will commence & complete (looking for Fielding to commence as early as February). We will also begin looking for common themes to explore with interview respondents during this time to present back to Alexion. We can opt to run qualitative research interviews to gather further insights. Quantitative data analysis begins. Begin drafting the Executive Summary.

  • APRIL

    Complete the draft of the Executive Summary of the ELAVAY: BIOADVOCATE BENCHMARK report is completed, and custom analyses are being developed/finalized. First-draft insights will be provided to partners for feedback, while an educational infographic will be developed for the respondent participants. At this time, ARCHO/ELAVAY develops press releases for public consumption, which will be distributed for review before publication.

  • APRIL-MAY

    The final reports, executive summaries, and custom reports will be finalized for ELAVAY BIOADVOCATE BENCHMARK partners and presented to our partners on their behalf. All final reports have considered any company-specific needs/storytelling to ensure senior leadership alignment and understanding. The report can be presented to as many internal teams as necessary.